Patel Vima, Gleeson Patrick K, Delaney Kathryn, Ralston Steven J, Feldman Scott, Fadugba Olajumoke
Section of Allergy and Immunology, Division of Pulmonary, Allergy and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Allergy and Asthma Specialists, LLC, Bluebell, Pennsylvania.
Section of Allergy and Immunology, Division of Pulmonary, Allergy and Critical Care Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Ann Allergy Asthma Immunol. 2022 May;128(5):568-574. doi: 10.1016/j.anai.2022.01.032. Epub 2022 Feb 2.
Penicillin allergy in pregnancy is associated with increased morbidity and the use of less effective antibiotics. Penicillin allergy evaluation in pregnancy is now recommended as per obstetrical guidelines but remains infrequent.
We studied pregnant women who underwent penicillin allergy evaluation in an allergy clinic to assess the effectiveness and safety of penicillin skin testing (PST) and incremental drug challenge (IDC) in pregnancy.
Index drug reactions, PST, and IDC results were reviewed. Antibiotic use, pregnancy outcomes, and pregnancy complications were compared with a control cohort of pregnant women with penicillin allergy who did not undergo allergy evaluation before delivery.
Penicillin allergy was evaluated in 136 women. Culprit drugs included penicillin (37%), amoxicillin (30%), and unknown (20%). Index reactions occurred greater than 5 years ago in 91%, and these reactions were cutaneous or unknown in 92%. Of the 133 patients who underwent skin testing, 131 (99%) had negative or equivocal results and proceeded to incremental challenge. All 131 women passed penicillin IDC. Of the 69 women who ultimately used intrapartum beta-lactam antibiotics, all but 1 patient tolerated them. Women who underwent penicillin allergy evaluation did not have an increased risk of cesarean delivery or other pregnancy complications when compared with women without penicillin allergy evaluation.
PST and IDC can be safely conducted in pregnant women. When evaluated as low risk, most women tolerate IDC and can receive penicillin intrapartum without adverse reactions or negative pregnancy outcomes.
孕期青霉素过敏与发病率增加以及使用效果较差的抗生素有关。目前根据产科指南建议对孕期进行青霉素过敏评估,但这种评估仍不常见。
我们研究了在过敏诊所接受青霉素过敏评估的孕妇,以评估孕期青霉素皮肤试验(PST)和递增药物激发试验(IDC)的有效性和安全性。
回顾了索引药物反应、PST和IDC结果。将抗生素使用情况、妊娠结局和妊娠并发症与分娩前未进行过敏评估的青霉素过敏孕妇对照组进行比较。
对136名女性进行了青霉素过敏评估。可疑药物包括青霉素(37%)、阿莫西林(30%)和不明药物(20%)。91%的索引反应发生在5年多以前,其中92%的反应为皮肤反应或不明反应。在133名接受皮肤试验的患者中,131名(99%)结果为阴性或不确定,随后进行了递增激发试验。所有131名女性均通过了青霉素IDC。在最终使用产时β-内酰胺类抗生素的69名女性中,除1名患者外,所有患者均耐受。与未进行青霉素过敏评估的女性相比,接受青霉素过敏评估的女性剖宫产或其他妊娠并发症的风险并未增加。
PST和IDC可在孕妇中安全进行。当评估为低风险时,大多数女性耐受IDC,并且可以在产时接受青霉素治疗而无不良反应或不良妊娠结局。